Evusheld long-acting antibody combination recommended for approval in the EU for the treatment of COVID-19
Recommendation based on TACKLE Phase III treatment data showing reduced risk of severe COVID-19 or death.AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency